로딩 중…
지수 로딩 중…
DAEWOONG CO.,LTD
003090· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩15,650+1.82%
2026-10-07
Financials
Valuation Metrics
DAEWOONG CO.,LTD's Market Cap is ₩9099B. At end of 2025 it was ₩1.3T. Ranked #335 of 2,419 in KR market (top 14%), #234 of 781 on KOSPI (top 30%), #37 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 909.92B KRW | KR#335/2,419 Sec#37/231 |
| Revenue | 2.12T KRW | KR#244/2,419 Sec#5/231 |
| Net Income | 221.65B KRW | KR#135/2,419 Sec#6/231 |
| Total Assets | 3.48T KRW | KR#217/2,419 Sec#5/231 |
| Net Assets | 1.88T KRW | KR#195/2,419 Sec#6/231 |
| Employees | 349 | KR#690/2,419 Sec#62/231 |
| Value | ||
| P/E | 4.11x | KR#251/2,419 Sec#9/231 |
| P/B | 0.48x | KR#744/2,419 Sec#31/231 |
| PEG | 0.04x | KR#282/2,419 Sec#16/231 |
| P/S | 0.43x | KR#796/2,419 Sec#31/231 |
| EV/EBITDA | 8.48x | KR#491/2,419 Sec#21/231 |
| FCF Yield | -4.09% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | 11.81% | KR#492/2,419 Sec#34/231 |
| ROA | 6.37% | KR#586/2,419 Sec#46/231 |
| Op. Margin | 11.30% | KR#452/2,419 Sec#41/231 |
| Revenue Growth | 4.55% | KR#1,222/2,419 Sec#120/231 |
| Earnings Growth | 96.76% | KR#402/2,419 Sec#28/231 |
| Financial Health | ||
| Debt Ratio | 85.23% | KR#1,413/2,419 Sec#162/231 |
| Total Debt | 1.39T KRW | KR#161/2,419 Sec#2/231 |
| FCF | -37.22B KRW | KR#2,024/2,419 Sec#198/231 |
| Cash | 267.79B KRW | KR#216/2,419 Sec#5/231 |
| Current Ratio | 1.01x | KR#1,708/2,419 Sec#171/231 |
| Net Debt/EBITDA | 4.68x | KR#1,008/2,419 Sec#74/231 |
| Dividend | ||
| Div. Yield | 1.27% | KR#1,029/2,419 Sec#56/231 |
| Div. Growth | 0.00% | KR—/2,419 Sec—/231 |
| Performance | ||
| 1Y Return | -28.21% | KR#1,646/2,419 Sec#131/231 |
| 1M Return | -7.56% | KR#2,100/2,419 Sec#202/231 |
| From 52W High | -48.86% | KR#1,488/2,419 Sec#119/231 |
| 1Y MDD | -48.59% | KR#936/2,419 Sec#74/231 |
| Trading | ||
| Volume | 69,069 shares | KR#1,365/2,419 Sec#137/231 |
| Trading Value | 1.07B KRW | KR#966/2,419 Sec#93/231 |
| Foreign Own. | 5.02% | KR#855/2,419 Sec#76/231 |
| Per Share | ||
| EPS | 3,812 KRW | KR#281/2,419 Sec#17/231 |
| BPS | 32,291 KRW | KR#345/2,419 Sec#23/231 |
Company Info
Daewoong, established in 1961 as Daehan Vitamin Industry Co., Ltd. and listed in 1973, transitioned to a holding company through a spin-off in 2002. As the holding company of a global healthcare group, it owns 36 subsidiaries including Daewoong Pharmaceutical, engaging in pharmaceutical manufacturing and investment. Daewoong focuses on enhancing global market penetration with Fexuclue, Enavlo, and Nabota, while strengthening K-Bio's status. The company is headquartered in Seongnam, Gyeonggi Province.